A Cluster for tuberculosis vaccine developement - TB VACCINE CLUSTER

Project Details

Description

The overall objective of the Cluster is to establish a framework for preclinical
development of novel tuberculosis vaccine candidates. We aim to identify optimal
strategies for generation of vaccine candidates by comparing innovative
approaches based on identification of novel protein antigens, characterisation of
non-protein antigens that elicit T cell responses in man, and construction of live
attenuated strains of mycobacteria. New vaccines will be compared alone or in
combination in standardised experimental challenge models to identify
candidates superior to the existing BCG vaccine. In parallel, the immunological
mechanisms underlying vaccine-induced protection will be characterised in man
and in experimental models. This information will be used to develop
immunological tests for initial clinical asse ssment of new vaccines. Integration of
these activites, with the participation of the top academic and industrial
researchers in Europe (Aventis Pasteur, SmithKline Beecham and the Statens
Serum Institut), is essential for completion of the final goal of bringing one or
more new vaccines to a stage suitable for clinical trials.
StatusFinished
Effective start/end date1/02/0031/12/03

Funding

  • European Commission: €4,999,996.00

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.